Safety and Feasibility of Thoracic Malignancy Surgery During the COVID-19 Pandemic.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
12 2021
Historique:
received: 16 06 2020
revised: 26 11 2020
accepted: 01 12 2020
pubmed: 18 12 2020
medline: 4 1 2022
entrez: 17 12 2020
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic has decreased surgical activity, particularly in the field of oncology, because of the suspicion of a higher risk of COVID-19-related severe events. This study aimed to investigate the feasibility and safety of thoracic cancer surgery in the most severely affected European and Canadian regions during the COVID-19 pandemic. The study investigators prospectively collected data on surgical procedures for malignant thoracic diseases from January 1 to April 30, 2020. The study included patients from 6 high-volume thoracic surgery departments: Nancy and Strasbourg (France), Freiburg (Germany), Milan and Turin (Italy), and Montreal (Canada). The centers involved in this research are all located in the most severely affected regions of those countries. An assessment of COVID-19-related symptoms, polymerase chain reaction (PCR)-confirmed COVID-19 infection, rates of hospital and intensive care unit admissions, and death was performed for each patient. Every deceased patient was tested for COVID-19 by PCR. In the study period, 731 patients who underwent 734 surgical procedures were included. In the whole cohort, 9 cases (1.2%) of COVID-19 were confirmed by PCR, including 5 in-hospital contaminants. Four patients (0.5%) needed readmission for oxygen requirements. In this subgroup, 2 patients (0.3%) needed intensive care unit and mechanical ventilatory support. The total number of deaths in the whole cohort was 22 (3%). A single death was related to COVID-19 (0.14%). Maintaining surgical oncologic activity in the era of the COVID-19 pandemic seems safe and feasible, with very low postoperative morbidity or mortality. To continue to offer the best care to patients who do not have COVID-19, reports on other diseases are urgently needed.

Sections du résumé

BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic has decreased surgical activity, particularly in the field of oncology, because of the suspicion of a higher risk of COVID-19-related severe events. This study aimed to investigate the feasibility and safety of thoracic cancer surgery in the most severely affected European and Canadian regions during the COVID-19 pandemic.
METHODS
The study investigators prospectively collected data on surgical procedures for malignant thoracic diseases from January 1 to April 30, 2020. The study included patients from 6 high-volume thoracic surgery departments: Nancy and Strasbourg (France), Freiburg (Germany), Milan and Turin (Italy), and Montreal (Canada). The centers involved in this research are all located in the most severely affected regions of those countries. An assessment of COVID-19-related symptoms, polymerase chain reaction (PCR)-confirmed COVID-19 infection, rates of hospital and intensive care unit admissions, and death was performed for each patient. Every deceased patient was tested for COVID-19 by PCR.
RESULTS
In the study period, 731 patients who underwent 734 surgical procedures were included. In the whole cohort, 9 cases (1.2%) of COVID-19 were confirmed by PCR, including 5 in-hospital contaminants. Four patients (0.5%) needed readmission for oxygen requirements. In this subgroup, 2 patients (0.3%) needed intensive care unit and mechanical ventilatory support. The total number of deaths in the whole cohort was 22 (3%). A single death was related to COVID-19 (0.14%).
CONCLUSIONS
Maintaining surgical oncologic activity in the era of the COVID-19 pandemic seems safe and feasible, with very low postoperative morbidity or mortality. To continue to offer the best care to patients who do not have COVID-19, reports on other diseases are urgently needed.

Identifiants

pubmed: 33333085
pii: S0003-4975(20)32115-9
doi: 10.1016/j.athoracsur.2020.12.001
pmc: PMC7834157
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1870-1876

Informations de copyright

Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Joseph Seitlinger (J)

Department of Thoracic Surgery, Nancy Regional University Hospital, Nancy, France.

Christophe Wollbrett (C)

Department of Thoracic Surgery, Nancy Regional University Hospital, Nancy, France.

Antonio Mazzella (A)

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

Severin Schmid (S)

Department of Thoracic Surgery, University Hospital Freiburg, Freiburg, Germany; Department of Thoracic Surgery and Upper Gastrointestinal Surgery, McGill University, Montreal, Canada.

Francesco Guerrera (F)

Thoracic Surgery Unit, University of Turin, Turin, Italy.

Douglas Banga Nkomo (D)

Department of Thoracic Surgery, Nancy Regional University Hospital, Nancy, France.

Mohamed Hassan (M)

Department of Thoracic Surgery, University Hospital Freiburg, Freiburg, Germany.

Aurélien Brindel (A)

Chest Department, Nancy Regional University Hospital, Nancy, France.

Julia Ruuth-Praz (J)

Chest Department, Nancy Regional University Hospital, Nancy, France.

Pierre Schmitt (P)

Chest Department, Sarreguemines Private Hospital, Sarreguemines, France.

Christelle Clément-Duchêne (C)

Department of Oncology, Lorraine Institute of Oncology, Nancy, France.

Nawal Douiri (N)

Department of Internal Medicine and Infectious Disease, Rhena Private Hospital, Strasbourg, France.

Jérémie Reeb (J)

Department of Thoracic Surgery, Rhena Private Hospital, Strasbourg, France.

Elena Prisciandaro (E)

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

Joelle Siat (J)

Department of Thoracic Surgery, Nancy Regional University Hospital, Nancy, France.

Lorenzo Spaggiari (L)

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

Enrico Ruffini (E)

Thoracic Surgery Unit, University of Turin, Turin, Italy.

Pierluigi Filosso (P)

Thoracic Surgery Unit, University of Turin, Turin, Italy.

Lorenzo Ferri (L)

Department of Thoracic Surgery and Upper Gastrointestinal Surgery, McGill University, Montreal, Canada.

Nicola Santelmo (N)

Department of Thoracic Surgery, Rhena Private Hospital, Strasbourg, France.

Jonathan Spicer (J)

Department of Thoracic Surgery and Upper Gastrointestinal Surgery, McGill University, Montreal, Canada.

Stéphane Renaud (S)

Department of Thoracic Surgery, Nancy Regional University Hospital, Nancy, France. Electronic address: sterenaud0@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH